Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

25 patients older than 65 years with metastatic breast cancer were treated with vinorelbine 30 mg/m(2) i.v. days 1 and 8 every 3 weeks; the pharmacokinetics were studied in 10 of them. Vinorelbine showed a large apparent volume of distribution (mean 23.4 1/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 1/kg). These results are similar to those reported in younger patients. No correlation has been found between toxicity, age and drug exposure. We observed 6 partial responses out of 20 evaluable patients despite a relatively low mean dose intensity (67%). Severe neutropenia occurred in 37% of the patients; other side-effects were acceptable. This study does not provide a pharmacokinetic rationale for reducing the dosage of vinorelbine in selected elderly patients. (C) 1997 Elsevier Science Ltd.